Edwards Lifesciences Corp — Director's Dealing 2024

May 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2024-05-07

Reporting Person: BOBO DONALD E JR (CVP,Strategy/Corp Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-07	Common Stock	A	6700.0000	$0.0000	Acquired	48368.7184	Direct
2024-05-07	Common Stock	F	619.0000	$85.0900	Disposed	47749.7184	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-07	Employee Stock Option (Right to Acquire)	$85.8400	A	39600.0000	Acquired	2031-05-06	Common Stock (39600.0000)	Direct
2024-05-07	Performance Rights	$	A	6700.0000	Acquired		Common Stock (6700.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	38615.0363	Indirect
Common Stock	135152.0000	Indirect

Footnotes

F1: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F2: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

F3: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.